Status and phase
Conditions
Treatments
About
The purpose of the first-in-human (FIH) study is to obtain safety, tolerability, and pharmacokinetic information on SAR442501 in a healthy adult volunteer population using an integrated single ascending dose (SAD)-multiple ascending dose (MAD) parallel cohort study design.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Primary purpose
Allocation
Interventional model
Masking
76 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal